Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.

15-40% of non-small cell lung cancer (NSCLC) patients harbor epidermal growth factor receptor (EGFR)-sensitizing mutations. Tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in this population, yet all patients will ultimately progress. Liquid biopsy can reliably identify somati...

Full description

Bibliographic Details
Main Authors: Hsiang-Ling Ho, Yuqiu Jiang, Chi-Lu Chiang, Sylwia Karwowska, Ranga Yerram, Keerti Sharma, Sidney Scudder, Chao-Hua Chiu, Chun-Ming Tsai, John F Palma, Abha Sharma, Teh-Ying Chou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0267362

Internet

https://doi.org/10.1371/journal.pone.0267362

Similar Items